Across TCGA pan-cancer cohorts, LINC01824 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC01824’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC01824 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01824 is over-expressed in tumor.
PRAD are the cancer types where LINC01824 tumor–normal differential expression is most reproducible.